CoChat
Sign Up
Cited by 37Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial

Open access
Richardson, Harriet, Ho, Vikki, Pasquet, Romain, Singh, Ravinder J., Goetz, Matthew P., Tu, Dongsheng, Goss, Paul E., Ingle, James N.·2020·Menopause
DOI 10.1097/gme.0000000000001568PMC PMC7469568
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The aim of the study was to quantify baseline estradiol (E2) and estrone (E1) concentrations according to selected patient characteristics in a substudy nested within the MAP.3 chemoprevention trial. METHODS: E2 and E1 levels were measured in 4,068 postmenopausal women using liquid chromatography-tandem mass spectrometry. Distributions were described by age, years since menopause, race, body mass index (BMI), smoking status, and use and duration of hormone therapy using the Kruskal-Wallis test. Multivariable linear regression was also used to identify characteristics associated with estrogen levels. RESULTS: After truncation at the 97.5th percentile, the mean (SD)/median (IQR) values for E2 and E1 were 5.41 (4.67)/4.0 (2.4-6.7) pg/mL and 24.7 (14.1)/21 (15-31) pg/mL, respectively. E2 and E1 were strongly correlated (Pearson correlation [r] = 0.8, P < 0.01). The largest variation in E2 and E1 levels was by BMI; mean E2 and E1 levels were 3.5 and 19.1 pg/mL, respectively for women with BMI less than 25 and 7.5 and 30.6 pg/mL, respectively, for women with BMI greater than 30. E2 and E1 varied by age, BMI, smoking status, and prior hormone therapy in multivariable models (P < 0.01). CONCLUSIONS: There was large interindividual variability observed for E2 and E1 that varied significantly by participant characteristics, but with small absolute differences except in the case of BMI. Although the majority of participant characteristics were independently associated with E1 and E2, together, these factors only explained about 20% of the variation in E1 and E2 levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/gme.0000000000001568

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both untreated girls with Turner syndrome with confirmed hypogonadism and post-menopausal women have E2 concentrations around 18 pmol L−1 (5 pg mL−1).

    “Both untreated girls with TS with confirmed hypogonadism and post-menopausal women have E2 concentrations around 18 pmol L−1 (5 pg mL−1).”

    From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [315]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Richardson, H., Ho, V., Pasquet, R., Singh, R. J., Goetz, M. P., Tu, D., Goss, P. E., & Ingle, J. N.
Affiliations
  • Queen's University (CA)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Mayo Clinic (US)
  • Harvard University (US)
Corresponding author
Richardson, Harriet
ORCID
Venue
Menopause
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2020-05-18
Volume
27
Issue
6
Pages
693-700
ISSN
  • 1072-3714 (ISSN-L)
  • 1530-0374
DOI
10.1097/gme.0000000000001568
PMC
PMC7469568
OpenAlex
W3027901360
Cited by
37
References
28
Citations by year
2026: 4 · 2025: 11 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 4
FWCI
2.64
Type
journal article
Language
en
Open access
Locations
  • Menopause The Journal of The North American Menopause Society (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P50CA116201)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords
estradiol, estrone, postmenopausal women, breast cancer chemoprevention, body mass index, hormone therapy, smoking status, racial differences, interindividual variability, baseline hormone levels
MeSH terms
Breast Neoplasms, Estradiol, Estrogens, Estrone, Female, Humans, Postmenopause, Chemoprevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review